With increasing investment in the anti-obesity market, monoacylglycerol acyltransferase 2 (MGAT2) is considered a pharmacological target for anti-obesity treatments [28,29]. This evidence concerns the gene MGAT2 and obesity due to melanocortin 4 receptor deficiency.